FREE DAILY STOCK MARKET NEWS

FREE DAILY STOCK MARKET NEWS

Biotech & Pharmaceutical News

Get latest biotech and pharmaceutical news and expert insights with The Market Bull.
 

The Latest Biotech & Pharmaceutical News

Market Update: Commodity correction hits ASX while AI shines

Market Update: Commodity correction hits ASX while AI shines

Global markets enjoyed a successful week, driven by the strength of the artificial intelligence (AI) industry and huge gains by Apple following the announcement of their new AI features. Meanwhile the ASX has taken a 1.5% hit during the shortened trading week due to...

Nutritional Growth Solutions secures A$2M capital raise

Nutritional Growth Solutions secures A$2M capital raise

Nutritional Growth Solutions (ASX:NGS) has received binding commitments for a A$2.0 million capital raise, facilitating investments in US sales and marketing to boost brand visibility and market penetration. Capital infusion The company successfully garnered A$2.0...

Firebrick’s share price surges following US Nasodine launch

Firebrick’s share price surges following US Nasodine launch

Firebrick Pharma (ASX:FRE) saw its share price skyrocket by over 80% this morning, following the release of its Nasodine Nasal Spray into the United States pharmaceutical market. The product is already on shelves and can be purchased from its dedicated US website....

2024 – The Year that Biotech Gets its Vibe Back?

2024 – The Year that Biotech Gets its Vibe Back?

2023 was a challenging year for a lot of listed Companies across the globe, as investor sentiment shifted from bad to worse. Companies operating in the pharmaceutical and biotechnology sectors, in particular, appeared to struggle to attract external investment, as the...

AdAlta Launches $1.23 Million Placement to Advance AD-214

AdAlta Launches $1.23 Million Placement to Advance AD-214

AdAlta Limited (ASX:1AD) is initiating a placement to secure up to A$1.23 million from sophisticated and professional investors to support the analysis of the Phase I extension clinical study for AD-214 and advance ongoing partnership discussions, offering additional...

FivepHusion’s Strategic Partnerships for Success

FivepHusion’s Strategic Partnerships for Success

FivepHusion recently embarked on a strategic partnership with pharmaceutical powerhouse Pfizer, facilitated through its manufacturing subsidiary Pfizer CentreOne®. This was not the first time the small biotech company used a mutually beneficial collaboration to its...

FivepHusion Reach Milestone in Deflexifol™ Clinical Trial

FivepHusion Reach Milestone in Deflexifol™ Clinical Trial

Treatment has commenced for the initial patient in the Deflexifol™ at Relapse Trial (DART), aimed at investigating paediatric ependymoma and other brain cancers, marking a pivotal moment in FivepHusion's journey towards bringing Deflexifol™ to the market. The...